Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy
Open Access
- 25 February 2025
- journal article
- review article
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (3) , 559-590
Abstract
Tumor-infiltrating myeloid cells (TIMs), which encompass tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), and tumor-associated dendritic cells (TADCs), are of great importance in tumor microenvironment (TME) and are integral to both pro- and anti-tumor immunity. Nevertheless, the phenotypic heterogeneity and functional plasticity of TIMs have posed challenges in fully understanding their complexity roles within the TME. Emerging evidence suggested that the presence of TIMs is frequently linked to prevention of cancer treatment and improvement of patient outcomes and survival. Given their pivotal function in the TME, TIMs have recently been recognized as critical targets for therapeutic approaches aimed at augmenting immunostimulatory myeloid cell populations while depleting or modifying those that are immunosuppressive. This review will explore the important properties of TIMs related to immunity, angiogenesis, and metastasis. We will also document the latest therapeutic strategies targeting TIMs in preclinical and clinical settings. Our objective is to illustrate the potential of TIMs as immunological targets that may improve the outcomes of existing cancer treatments.Keywords
This publication has 431 references indexed in Scilit:
- Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell ResponsesCancer Research, 2004
- Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.2003
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunityNature Medicine, 2003
- Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.2003
- Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic studyGastroenterology, 2003
- Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity.2001
- The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated MacrophagesThe American Journal of Pathology, 2000
- Proinflammatory Mediators Stimulate Neutrophil-Directed AngiogenesisArchives of Surgery, 1999
- TGF-β1 regulation of dendritic cellsMicrobes and Infection, 1999
- A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid TumorsJNCI: Journal of the National Cancer Institute, 1976